Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Calm After Storm | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 4.77% | |
Volume Surge | Other | 4.77% | |
Calm After Storm | Range Contraction | 4.77% | |
Narrow Range Bar | Range Contraction | 4.77% | |
Lower Bollinger Band Walk | Weakness | 4.77% |
Alert | Time |
---|---|
Possible Inside Day | about 18 hours ago |
Down 5% | about 22 hours ago |
Down 10% | about 22 hours ago |
2x Volume Pace | about 22 hours ago |
1.5x Volume Pace | about 22 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 10/31/2024
Syros Pharmaceuticals, Inc. Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Medication Acute Myeloid Leukemia Leukemia Myelodysplastic Syndrome Immune Mediated Diseases Acute Leukemia Refractory Acute Myeloid Leukemia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.17 |
52 Week Low | 0.183 |
Average Volume | 9,690,425 |
200-Day Moving Average | 4.38 |
50-Day Moving Average | 1.91 |
20-Day Moving Average | 1.81 |
10-Day Moving Average | 1.28 |
Average True Range | 0.34 |
RSI (14) | 29.08 |
ADX | 31.31 |
+DI | 23.86 |
-DI | 42.75 |
Chandelier Exit (Long, 3 ATRs) | 2.37 |
Chandelier Exit (Short, 3 ATRs) | 1.21 |
Upper Bollinger Bands | 3.88 |
Lower Bollinger Band | -0.26 |
Percent B (%b) | 0.13 |
BandWidth | 228.65 |
MACD Line | -0.49 |
MACD Signal Line | -0.23 |
MACD Histogram | -0.2614 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.37 | ||||
Resistance 3 (R3) | 0.36 | 0.33 | 0.35 | ||
Resistance 2 (R2) | 0.33 | 0.31 | 0.33 | 0.35 | |
Resistance 1 (R1) | 0.31 | 0.30 | 0.32 | 0.32 | 0.35 |
Pivot Point | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 |
Support 1 (S1) | 0.26 | 0.26 | 0.26 | 0.26 | 0.23 |
Support 2 (S2) | 0.23 | 0.25 | 0.23 | 0.23 | |
Support 3 (S3) | 0.21 | 0.23 | 0.23 | ||
Support 4 (S4) | 0.21 |